Switch to:
Also traded in: Brazil, France, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.21
NYSE:ABBV's Cash to Debt is ranked lower than
82% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.56 vs. NYSE:ABBV: 0.21 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:ABBV' s Cash to Debt Range Over the Past 10 Years
Min: 0.21  Med: 0.63 Max: No Debt
Current: 0.21
Equity to Asset 0.10
NYSE:ABBV's Equity to Asset is ranked lower than
96% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:ABBV: 0.10 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:ABBV' s Equity to Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.12 Max: 0.69
Current: 0.1
-0.01
0.69
Interest Coverage 9.73
NYSE:ABBV's Interest Coverage is ranked lower than
74% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.94 vs. NYSE:ABBV: 9.73 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ABBV' s Interest Coverage Range Over the Past 10 Years
Min: 7.95  Med: 55.93 Max: No Debt
Current: 9.73
F-Score: 6
Z-Score: 2.03
M-Score: -2.32
WACC vs ROIC
11.43%
23.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 36.21
NYSE:ABBV's Operating margin (%) is ranked higher than
95% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.61 vs. NYSE:ABBV: 36.21 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:ABBV' s Operating margin (%) Range Over the Past 10 Years
Min: 17.09  Med: 30.16 Max: 36.21
Current: 36.21
17.09
36.21
Net-margin (%) 24.08
NYSE:ABBV's Net-margin (%) is ranked higher than
92% of the 732 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.89 vs. NYSE:ABBV: 24.08 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:ABBV' s Net-margin (%) Range Over the Past 10 Years
Min: 8.89  Med: 22.5 Max: 32.62
Current: 24.08
8.89
32.62
ROE (%) 118.92
NYSE:ABBV's ROE (%) is ranked higher than
99% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. NYSE:ABBV: 118.92 )
Ranked among companies with meaningful ROE (%) only.
NYSE:ABBV' s ROE (%) Range Over the Past 10 Years
Min: 24.85  Med: 74 Max: 199.32
Current: 118.92
24.85
199.32
ROA (%) 10.29
NYSE:ABBV's ROA (%) is ranked higher than
79% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.58 vs. NYSE:ABBV: 10.29 )
Ranked among companies with meaningful ROA (%) only.
NYSE:ABBV' s ROA (%) Range Over the Past 10 Years
Min: 6.26  Med: 15.79 Max: 39.54
Current: 10.29
6.26
39.54
ROC (Joel Greenblatt) (%) 321.28
NYSE:ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.31 vs. NYSE:ABBV: 321.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:ABBV' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 75.1  Med: 144.26 Max: 321.28
Current: 321.28
75.1
321.28
Revenue Growth (3Y)(%) 6.20
NYSE:ABBV's Revenue Growth (3Y)(%) is ranked higher than
52% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. NYSE:ABBV: 6.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:ABBV' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 4.8 Max: 6.2
Current: 6.2
0
6.2
EBITDA Growth (3Y)(%) 4.20
NYSE:ABBV's EBITDA Growth (3Y)(%) is ranked lower than
61% of the 568 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. NYSE:ABBV: 4.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:ABBV' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -4.3 Max: 4.2
Current: 4.2
0
4.2
EPS Growth (3Y)(%) -2.20
NYSE:ABBV's EPS Growth (3Y)(%) is ranked lower than
64% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. NYSE:ABBV: -2.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:ABBV' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -11.3 Max: -1.1
Current: -2.2
GuruFocus has detected 4 Warning Signs with AbbVie Inc $NYSE:ABBV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:ABBV's 10-Y Financials

Financials (Next Earnings Date: 2017-01-27)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

ABBV Guru Trades in Q1 2016

Lee Ainslie 43,170 sh (New)
Joel Greenblatt 645,835 sh (+216.32%)
Jim Simons 1,563,056 sh (+168.22%)
David Dreman 30,542 sh (+16.28%)
Pioneer Investments 1,261,434 sh (+9.68%)
NWQ Managers 781,850 sh (+3.64%)
Scott Black 41,959 sh (+2.85%)
Jeff Auxier 20,572 sh (+1.48%)
Larry Robbins 13,686,588 sh (+1.05%)
Mairs and Power 268,191 sh (+0.52%)
Murray Stahl 36,154 sh (+0.37%)
Robert Bruce 232,915 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
John Paulson Sold Out
Louis Moore Bacon Sold Out
Dodge & Cox 33,232 sh (-0.07%)
PRIMECAP Management 1,022,845 sh (-12.21%)
Mario Gabelli 35,460 sh (-12.66%)
Ken Fisher 743,284 sh (-20.51%)
First Pacific Advisors 56,050 sh (-25.76%)
Tom Russo 21,718 sh (-74.96%)
Paul Tudor Jones 4,100 sh (-87.55%)
» More
Q2 2016

ABBV Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 159,258 sh (New)
Stanley Druckenmiller 1,324,920 sh (New)
Joel Greenblatt 905,598 sh (+40.22%)
Lee Ainslie 50,540 sh (+17.07%)
Pioneer Investments 1,281,950 sh (+1.63%)
Jeff Auxier 20,672 sh (+0.49%)
Mairs and Power 269,153 sh (+0.36%)
Robert Bruce 232,915 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Samuel Isaly 1,225,000 sh (unchged)
First Pacific Advisors Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 35,296 sh (-0.46%)
Murray Stahl 34,755 sh (-3.87%)
PRIMECAP Management 979,845 sh (-4.20%)
Scott Black 40,138 sh (-4.34%)
Ken Fisher 693,394 sh (-6.71%)
Larry Robbins 12,454,488 sh (-9.00%)
Tom Russo 17,106 sh (-21.24%)
Jim Simons 1,217,600 sh (-22.10%)
NWQ Managers 562,288 sh (-28.08%)
David Dreman 15,897 sh (-47.95%)
» More
Q3 2016

ABBV Guru Trades in Q3 2016

Paul Tudor Jones 8,900 sh (New)
Jim Simons 1,918,456 sh (+57.56%)
Murray Stahl 35,056 sh (+0.87%)
Tom Russo 17,106 sh (unchged)
Stanley Druckenmiller 1,324,920 sh (unchged)
Robert Bruce 232,915 sh (unchged)
Dodge & Cox 33,232 sh (unchged)
Jeff Auxier 20,622 sh (-0.24%)
Mairs and Power 266,453 sh (-1.00%)
Manning & Napier Advisors, Inc 157,543 sh (-1.08%)
Ken Fisher 684,042 sh (-1.35%)
Lee Ainslie 49,600 sh (-1.86%)
PRIMECAP Management 953,845 sh (-2.65%)
David Dreman 15,019 sh (-5.52%)
Scott Black 36,748 sh (-8.45%)
Pioneer Investments 1,130,994 sh (-11.78%)
Joel Greenblatt 684,356 sh (-24.43%)
Mario Gabelli 20,196 sh (-42.78%)
Larry Robbins 6,030,141 sh (-51.58%)
NWQ Managers 146,743 sh (-73.90%)
Samuel Isaly 742,955 sh (-39.35%)
» More
Q4 2016

ABBV Guru Trades in Q4 2016

Ken Fisher 696,569 sh (+1.83%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 5122
Compare:NYSE:SNY, NYSE:BMY, OTCPK:GLAXF, OTCPK:BAYZF, NYSE:LLY, NYSE:AZN, NYSE:MRK, NYSE:NVS, OTCPK:ALPMY, OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:CHPTY, OTCPK:PTKFY, OTCPK:SNPHY, NYSE:PFE, OTCPK:GWPRF, NAS:HCM, OTCPK:HAWPF » details
Traded in other countries:ABBV34.Brazil, ABBV.France, 4AB.Germany, ABBV.Mexico, ABBV.Switzerland, 0QCV.UK,
AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc is a research-based biopharmaceutical company incorporated in Delaware on April 10, 2012. The Company is engaged in the discovery, development, manufacture and sale of a broad line of pharmaceutical products. It develops and markets therapies that address some of the world's complex and serious diseases. It products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. It also has a pipeline of new medicines, including more than 50 compounds or indications in clinical development across such important medical specialties as immunology, virology/liver disease, oncology, neurological diseases and women's health. The Company's products offering includes HUMIRA, IMBRUVICA, VIEKIRA, Creon, Synagis, Lupron, Synthroid, Kaletra, AndroGel, Sevoflurane, Duodopa, Dyslipidemia products, and other products. The Company's products are sold directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from AbbVie-owned distribution centers and public warehouses. The Company faces competition from other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics. The manufacture, marketing, sale, promotion, and distribution of AbbVie's products are subject to comprehensive government regulation.

Top Ranked Articles about AbbVie Inc

Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients Japan has one of the highest rates of hepatitis C in the industrialized world
Enanta Pharmaceuticals Inc. (NASDAQ:ENTAannounced on Monday the results of the Phase 3 CERTAIN-1 study done in collaboration with AbbVie (NYSE:ABBV) that assessed the safety and efficacy of AbbVie’s investigational regimen of glecaprevir/pibrentasvir (G/P) in Japanese patients infected with genotype 1 chronic hepatitis C virus without cirrhosis. Read more...
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Researchers observed a decline in sweat chloride concentration
Galapagos NV (NASDAQ:GLPG), the Belgian clinical-stage biotechnology company that collaborated with AbbVie Inc. (NYSE:ABBV) on a treatment for patients affected with cystic fibrosis, announced last week the “topline results from its SAPHIRA 1 Phase 2 study in cystic fibrosis patients with potentiator GLPG1837.” Read more...
AbbVie Files for Approval of Hepatitis C Treatment in the US The application is backed by relevant results and the company will apply in Europe in the first quarter of 2017
AbbVie (NYSE:ABBV) announced today through PRNewswire that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its “investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).” Read more...
Express Scripts to Include Harvoni in Hepatitis Cure Value Program The treatment cost will be reduced close to 50%
As announced by Express Scripts (NASDAQ:ESRX) through PR Newswire Dec. 12, the program that targets the treatment of patients affected with the hepatitis C virus, called “Hepatitis Cure Value Program,” will be upgraded with another product in January. Read more...
Roche's Leukemia Drug Approved for Next Step in Europe Venclyxto drug gets 'conditional marketing' approval from European Commission
Roche (RHHBY) announced on Dec. 8 that Venclyxto (venetoclax), a drug that is used as therapy in patients chronically affected with lymphocytic leukemia, has been authorized by the European Commission, achieving the “conditional marketing.” Read more...
Transplant Patients Show Improvement With Imbruvica Researchers observed a general response rate of 67%
AbbVie Inc. (NYSE:ABBV) announced Tuesday through PR Newswire that results indicate ibrutinib (trade name Imbruvica), a type of chemotherapy drug for the treatment of patients suffering from “chronic graft-versus-host disease (cGVHD),” is effective and safe. Read more...
AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients Researchers observed a general response rate of 48%
On Dec. 5, AbbVie Inc. (NYSE:ABBV) announced through PR Newswire the results regarding whether ibrutinib (Imbruvica), a type of chemotherapy drug for the treatment of patients suffering from relapsed / refractory marginal zone lymphoma (MZL), is effective and safe. Read more...
Leukemia Treatment Achieves Promising Results 88% of patients got complete marrow response
Juno Therapeutics Inc. (NASDAQ:JUNO) communicated through the Business Wire on Dec. 3 that the results from the study undertaken in patients affected with lymphocytic leukemia (CLL) and treated with JCAR014 were promising. Read more...
FDA Orphan Drug Designation for AbbVie's Risankizumab Medicine will be tested as Crohn's disease treatment in young patients
AbbVie (NYSE:ABBV) announced through PR Newswire Wednesday that risankizumab (ABBV-066; formerly BI 655066), an interleukin-23 (IL-23) inhibitor, received the Orphan Drug Designation status from the U.S. Food and Drug Administration (FDA) for the treatment of Crohn's disease in patients who are younger than 18 years. Read more...
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Humira and M923 show equivalent results in moderate-to-severe chronic plaque psoriasis patients
Momenta Pharmaceuticals (NASDAQ:MNTA) announced yesterday that the results from the “confirmatory, randomized, double-blind, multicenter study of M923 in adult patients with moderate-to-severe chronic plaque psoriasis” are equivalent to AbbVie's (NYSE:ABBV) Humira in terms of the therapy’s efficacy, safety and body’s immune response after a treatment period of 16 weeks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 16.67
ABBV's P/E(ttm) is ranked higher than
76% of the 531 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.62 vs. ABBV: 16.67 )
Ranked among companies with meaningful P/E(ttm) only.
ABBV' s P/E(ttm) Range Over the Past 10 Years
Min: 9.85  Med: 18.89 Max: 63.37
Current: 16.67
9.85
63.37
Forward P/E 11.25
ABBV's Forward P/E is ranked higher than
75% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.95 vs. ABBV: 11.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 16.67
ABBV's PE(NRI) is ranked higher than
75% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.66 vs. ABBV: 16.67 )
Ranked among companies with meaningful PE(NRI) only.
ABBV' s PE(NRI) Range Over the Past 10 Years
Min: 9.85  Med: 18.89 Max: 63.37
Current: 16.67
9.85
63.37
Price/Owner Earnings (ttm) 17.91
ABBV's Price/Owner Earnings (ttm) is ranked higher than
73% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.46 vs. ABBV: 17.91 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ABBV' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 13.74  Med: 17.48 Max: 57.24
Current: 17.91
13.74
57.24
P/B 15.49
ABBV's P/B is ranked lower than
96% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. ABBV: 15.49 )
Ranked among companies with meaningful P/B only.
ABBV' s P/B Range Over the Past 10 Years
Min: 14.08  Med: 19.99 Max: 76.98
Current: 15.49
14.08
76.98
P/S 3.98
ABBV's P/S is ranked lower than
61% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.91 vs. ABBV: 3.98 )
Ranked among companies with meaningful P/S only.
ABBV' s P/S Range Over the Past 10 Years
Min: 2.83  Med: 4.21 Max: 5.67
Current: 3.98
2.83
5.67
PFCF 14.48
ABBV's PFCF is ranked higher than
69% of the 200 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.43 vs. ABBV: 14.48 )
Ranked among companies with meaningful PFCF only.
ABBV' s PFCF Range Over the Past 10 Years
Min: 8.66  Med: 14.46 Max: 38.18
Current: 14.48
8.66
38.18
POCF 13.49
ABBV's POCF is ranked higher than
61% of the 267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.46 vs. ABBV: 13.49 )
Ranked among companies with meaningful POCF only.
ABBV' s POCF Range Over the Past 10 Years
Min: 8.2  Med: 13.44 Max: 31.6
Current: 13.49
8.2
31.6
EV-to-EBIT 14.81
ABBV's EV-to-EBIT is ranked higher than
67% of the 536 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.56 vs. ABBV: 14.81 )
Ranked among companies with meaningful EV-to-EBIT only.
ABBV' s EV-to-EBIT Range Over the Past 10 Years
Min: 10.2  Med: 15.6 Max: 42.5
Current: 14.81
10.2
42.5
EV-to-EBITDA 13.13
ABBV's EV-to-EBITDA is ranked higher than
65% of the 561 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.22 vs. ABBV: 13.13 )
Ranked among companies with meaningful EV-to-EBITDA only.
ABBV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.6  Med: 13.7 Max: 34.1
Current: 13.13
8.6
34.1
PEG 24.00
ABBV's PEG is ranked lower than
94% of the 281 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.91 vs. ABBV: 24.00 )
Ranked among companies with meaningful PEG only.
ABBV' s PEG Range Over the Past 10 Years
Min: 2.03  Med: 2.25 Max: 24
Current: 24
2.03
24
Current Ratio 1.79
ABBV's Current Ratio is ranked lower than
61% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.34 vs. ABBV: 1.79 )
Ranked among companies with meaningful Current Ratio only.
ABBV' s Current Ratio Range Over the Past 10 Years
Min: 1.22  Med: 1.92 Max: 2.82
Current: 1.79
1.22
2.82
Quick Ratio 1.61
ABBV's Quick Ratio is ranked lower than
55% of the 769 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.76 vs. ABBV: 1.61 )
Ranked among companies with meaningful Quick Ratio only.
ABBV' s Quick Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.72 Max: 2.65
Current: 1.61
1.06
2.65
Days Inventory 110.84
ABBV's Days Inventory is ranked higher than
52% of the 680 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.19 vs. ABBV: 110.84 )
Ranked among companies with meaningful Days Inventory only.
ABBV' s Days Inventory Range Over the Past 10 Years
Min: 35.55  Med: 84.38 Max: 115.3
Current: 110.84
35.55
115.3
Days Sales Outstanding 72.29
ABBV's Days Sales Outstanding is ranked higher than
53% of the 622 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.25 vs. ABBV: 72.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
ABBV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 68.3  Med: 79.3 Max: 93.3
Current: 72.29
68.3
93.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.82
ABBV's Dividend Yield is ranked higher than
86% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. ABBV: 3.82 )
Ranked among companies with meaningful Dividend Yield only.
ABBV' s Dividend Yield Range Over the Past 10 Years
Min: 0.85  Med: 3.02 Max: 3.96
Current: 3.82
0.85
3.96
Dividend Payout 0.60
ABBV's Dividend Payout is ranked higher than
82% of the 389 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. ABBV: 0.60 )
Ranked among companies with meaningful Dividend Payout only.
ABBV' s Dividend Payout Range Over the Past 10 Years
Min: 0.6  Med: 0.65 Max: 1.51
Current: 0.6
0.6
1.51
Forward Dividend Yield 4.14
ABBV's Forward Dividend Yield is ranked higher than
89% of the 609 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.62 vs. ABBV: 4.14 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 3.82
ABBV's Yield on cost (5-Year) is ranked higher than
73% of the 779 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.17 vs. ABBV: 3.82 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ABBV' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.85  Med: 3.02 Max: 3.96
Current: 3.82
0.85
3.96
3-Year Average Share Buyback Ratio -0.70
ABBV's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 429 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.40 vs. ABBV: -0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ABBV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.7  Med: -0.25 Max: 0
Current: -0.7
-0.7
0

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.77
ABBV's Price/Projected FCF is ranked higher than
64% of the 314 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.69 vs. ABBV: 1.77 )
Ranked among companies with meaningful Price/Projected FCF only.
ABBV' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.71  Med: 1.76 Max: 1.81
Current: 1.77
1.71
1.81
Price/Median PS Value 0.95
ABBV's Price/Median PS Value is ranked higher than
67% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. ABBV: 0.95 )
Ranked among companies with meaningful Price/Median PS Value only.
ABBV' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.7  Med: 0.99 Max: 1.25
Current: 0.95
0.7
1.25
Price/Peter Lynch Fair Value 2.28
ABBV's Price/Peter Lynch Fair Value is ranked lower than
66% of the 150 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. ABBV: 2.28 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ABBV' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 2.1  Med: 2.22 Max: 2.33
Current: 2.28
2.1
2.33
Earnings Yield (Greenblatt) (%) 6.73
ABBV's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.20 vs. ABBV: 6.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ABBV' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 2.4  Med: 6.4 Max: 9.8
Current: 6.73
2.4
9.8
Forward Rate of Return (Yacktman) (%) 12.96
ABBV's Forward Rate of Return (Yacktman) (%) is ranked higher than
59% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.63 vs. ABBV: 12.96 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ABBV' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 12.7  Med: 13.1 Max: 14.5
Current: 12.96
12.7
14.5

More Statistics

Revenue (TTM) (Mil) $25,242
EPS (TTM) $ 3.70
Beta1.49
Short Percentage of Float2.07%
52-Week Range $51.60 - 68.12
Shares Outstanding (Mil)1,625.10

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 25,717 28,028 30,206 33,157
EPS ($) 4.79 5.45 6.23 7.32
EPS w/o NRI ($) 4.79 5.45 6.23 7.32
EPS Growth Rate
(3Y to 5Y Estimate)
5.73%
Dividends Per Share ($) 2.28 2.52 2.64
» More Articles for NYSE:ABBV

Headlines

Articles On GuruFocus.com
Adient Stock: Still Undervalued After Johnson Controls Spinoff Jan 16 2017 
Entana Pharmaceuticals Releases Results of AbbVie Hepatitis Treatment in Japanese Patients Jan 11 2017 
Pfizer Inc.: Humira's Biosimilar Meets Primary Endpoint Jan 10 2017 
10 Stocks for Using a Benjamin Graham Value Investing Strategy Jan 10 2017 
The Best DRIP Stocks: 15 No-Fee Dividend Aristocrats Jan 09 2017 
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Jan 05 2017 
Lannet's Lopinavir, Ritonavir Approved to Treat HIV in US Jan 05 2017 
These Biotech Stocks Could Run in 2017 Jan 04 2017 
Discounted Stocks: Apple, Accenture, Aaron's Jan 03 2017 
Galapagos NV Announces Results From Cystic Fibrosis Treatment Study Dec 27 2016 

More From Other Websites
Orphan Drugs Among 2015's Top 10 Best-Selling Medications Jan 18 2017
[$$] Biotech M&A Deals Expected to Increase in 2017 Jan 17 2017
Adient Stock: Still Undervalued After Johnson Controls Spinoff Jan 16 2017
10 Best Dividend-Paying Stocks for 2017 Jan 13 2017
AbbVie, Inc. – Value Analysis (NYSE:ABBV) : January 13, 2017 Jan 13 2017
Coherus Offers Positive Phase III Data on Humira Biosimilar Jan 13 2017
12 Health Benefits of Medical Marijuana According To Publicly Traded Weed Companies Jan 12 2017
AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : January 12, 2017 Jan 12 2017
Entana Pharmaceuticals Releases Study Results of Hepatitis Treatment in Japanese Patients Jan 11 2017
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short Jan 11 2017
Emergent Technologies’ Pure MHC Explores A New Collaboration With AbbVie Inc (ABBV) Jan 10 2017
AbbVie to Host Fourth-Quarter 2016 Earnings Conference Call Jan 10 2017
AbbVie's HCV Combo Favorable in Japanese Phase III Study Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal Jan 10 2017
Japan's Takeda ready for fresh acquisitions after $5.2 bln Ariad deal Jan 10 2017
The Best DRIP Stocks: 15 No-Fee Dividend Aristocrats Jan 09 2017
Pure MHC to Partner with AbbVie on Oncology Research Jan 09 2017
AbbVie, Genomics Medicine Ireland and WuXi NextCODE Announce Landmark Population Genomics Alliance Jan 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)